Genetic polymorphism of CCR5 gene and HIV disease: the heterozygous (CCR5/delta ccr5) genotype is neither essential nor sufficient for protection against disease progression. Swiss HIV Cohort - PubMed (original) (raw)
. 1997 Dec;27(12):3223-7.
doi: 10.1002/eji.1830271220.
G P Rizzardi, D Glauser, O Rutschmann, B Hirschel, L Perrin, M Opravil, M Flepp, J von Overbeck, M P Glauser, S Ghezzi, E Vicenzi, G Poli, A Lazzarin, G Pantaleo
Affiliations
- PMID: 9464809
- DOI: 10.1002/eji.1830271220
Genetic polymorphism of CCR5 gene and HIV disease: the heterozygous (CCR5/delta ccr5) genotype is neither essential nor sufficient for protection against disease progression. Swiss HIV Cohort
R A Morawetz et al. Eur J Immunol. 1997 Dec.
Abstract
Homozygous (delta ccr5/delta ccr5) and heterozygous (CCR5/delta ccr5) deletions in the beta-chemokine receptor 5 (CCR5) gene, which encodes for the major co-receptor for macrophage-tropic HIV-1 entry, have been implicated in resistance to HIV infection and in protection against disease progression, respectively. The CCR5/delta ccr5 genotype was found more frequently in long-term nonprogressors (LTNP) (31.0%) than in progressors (10.6%, p < 0.0001), in agreement with previous studies. Kaplan-Meier survival analyses showed that a slower progression of disease, i.e. higher proportion of subjects with CD4+ T cell counts > 500/microl (p = 0.0006) and a trend toward a slower progression to AIDS (p = 0.077), was associated with the CCR5/delta ccr5 genotype. However, when LTNP were analyzed separately, no significant differences in CD4+ T cell counts (p = 0.12) and viremia levels (p = 0.65) were observed between the wild-type (69% of LTNP) and the heterozygous (31.0%) genotypes. Therefore, there are other factors which play a major role in determining the status of nonprogression in the majority of LTNP. Furthermore, there was no evidence that the CCR5/delta ccr5 genotype was associated with different rates of disease progression in the group of progressors. Taken together, these results indicate that the CCR5/delta ccr5 genotype is neither essential nor sufficient for protection against the progression of HIV disease.
Similar articles
- Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors.
Cohen OJ, Vaccarezza M, Lam GK, Baird BF, Wildt K, Murphy PM, Zimmerman PA, Nutman TB, Fox CH, Hoover S, Adelsberger J, Baseler M, Arthos J, Davey RT Jr, Dewar RL, Metcalf J, Schwartzentruber DJ, Orenstein JM, Buchbinder S, Saah AJ, Detels R, Phair J, Rinaldo C, Margolick JB, Pantaleo G, Fauci AS. Cohen OJ, et al. J Clin Invest. 1997 Sep 15;100(6):1581-9. doi: 10.1172/JCI119682. J Clin Invest. 1997. PMID: 9294127 Free PMC article. - CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection.
de Roda Husman AM, Blaak H, Brouwer M, Schuitemaker H. de Roda Husman AM, et al. J Immunol. 1999 Oct 15;163(8):4597-603. J Immunol. 1999. PMID: 10510404 - Chemokine receptor allelic polymorphisms: relationships to HIV resistance and disease progression.
Paxton WA, Kang S. Paxton WA, et al. Semin Immunol. 1998 Jun;10(3):187-94. doi: 10.1006/smim.1998.0132. Semin Immunol. 1998. PMID: 9653045 Review. - The chemokine receptor CCR5 in the central nervous system.
Sorce S, Myburgh R, Krause KH. Sorce S, et al. Prog Neurobiol. 2011 Feb;93(2):297-311. doi: 10.1016/j.pneurobio.2010.12.003. Epub 2010 Dec 14. Prog Neurobiol. 2011. PMID: 21163326 Review.
Cited by
- CCR5 as a Coreceptor for Human Immunodeficiency Virus and Simian Immunodeficiency Viruses: A Prototypic Love-Hate Affair.
Jasinska AJ, Pandrea I, Apetrei C. Jasinska AJ, et al. Front Immunol. 2022 Jan 27;13:835994. doi: 10.3389/fimmu.2022.835994. eCollection 2022. Front Immunol. 2022. PMID: 35154162 Free PMC article. Review. - Genetic variation in the chemokine receptor 5 gene and course of HIV infection; review on genetics and immunological aspect.
Verma MK, Shakya S. Verma MK, et al. Genes Dis. 2020 Apr 18;8(4):475-483. doi: 10.1016/j.gendis.2020.04.007. eCollection 2021 Jul. Genes Dis. 2020. PMID: 34179311 Free PMC article. Review. - The number of CCR5 expressing CD4+ T lymphocytes is lower in HIV-infected long-term non-progressors with viral control compared to normal progressors: a cross-sectional study.
Meijerink H, Indrati AR, van Crevel R, Joosten I, Koenen H, van der Ven AJ. Meijerink H, et al. BMC Infect Dis. 2014 Dec 13;14:683. doi: 10.1186/s12879-014-0683-0. BMC Infect Dis. 2014. PMID: 25495598 Free PMC article. - Innate and Adaptive Immunity in Long-Term Non-Progression in HIV Disease.
Zaunders J, van Bockel D. Zaunders J, et al. Front Immunol. 2013 Apr 24;4:95. doi: 10.3389/fimmu.2013.00095. eCollection 2013. Front Immunol. 2013. PMID: 23630526 Free PMC article. - Risk of HIV Infection and Lethality Are Decreased in CCR5del32 Heterozygotes: Focus Nosocomial Infection Study and Meta-analysis.
Borinskaya SA, Kozhekbaeva ZhM, Zalesov AV, Olseeva EV, Maksimov AR, Kutsev SI, Garaev MM, Rubanovich AV, Yankovsky NK. Borinskaya SA, et al. Acta Naturae. 2012 Jan;4(1):42-52. Acta Naturae. 2012. PMID: 22708062 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials